Perspective: How will healthcare reform affect cancer care?

Article

In this video interview, Oncology board member and CancerNetwork contributing editor, Derek Raghavan, MD, PhD, Institute Chair, Taussig Cancer Institute gives his opinion on how the changing landscape of the American healthcare system will affect cancer care.

In this video interview, Oncology board member and CancerNetwork contributing editor, Derek Raghavan, M.D., Ph.D, Institute Chair, Taussig Cancer Institute gives his opinion on how the changing landscape of the American healthcare system will affect cancer care.

Interview: news.cancerconnect.com/asco-2010-how-will-healthcare-reform-affect-cancer-care/

Perspectives and concerns about the affects of Obama-care abound…

On July, 14th the Community Oncology Alliance (COA) announced that due to severe year after year cuts to Medicare reimbursement for cancer care, community oncologists around the US are closing offices at a rate rapidly increasing since January 2010. Reductions in staff, services and facilities are also on the rise.

“As a practicing oncologist, I am extremely concerned about the impact these closings have on
patients. Many are simply falling through the cracks as providers are being forced to cut staff and
close clinics, forcing patients to seek treatments outside of their communities,” said David Eagle,
MD, newly elected President of COA.

--Look here for continuing coverage and analysis of the policies coming from Capitol Hill that directly impact the delivery of oncology services across the country.

 

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content